Sign in
Not yet recruitingPhase 3

A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Botswana, Eswatini, Malawi, and Uganda4 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
580 people, planned
Starts
30 Nov 2026
Expected to end
10 Jul 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Doxycycline hyclate
  • Standard of Care for STI prevention
Record updated
20 October 2026

Who can take part

Age
13 years to 34 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • All adolescent and adult young women who meet all the following criteria are eligible for inclusion in this study:
  • Age 13-34 years, inclusive
  • In good health as determined by past medical history, medication use, and targeted physical examination,; If not living with HIV, negative HIV test conducted at screening; If living with HIV, on an antiretroviral regimen for ≥3 months
  • Report at least two of the following:; Treatment for a curable STI (not including HIV) in the past 12 months prior to screening; Self-report of condomless (oral, vaginal, and/or anal) intercourse at least once in the 30 days prior to screening; Has had two or more partners in the past 6 months
  • ≥ 45 kilograms (99 pounds) in weight
  • Anticipate living in the study area for 12 months and no plans for travel away from the study site for a time period that would interfere with product resupply and study participation
  • Willing to undergo all required study procedures that may include Directly/Video observed therapy (D/VOT); and
  • Provide written informed consent to participate in the study; If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with Institutional Review Board (IRB)/Ethics Committee (EC) policies: Willing and able to provide written informed consent for study participation; If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB/EC policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation

Who cannot take part

  • Current (within 30 days of Enrollment) or anticipated use of a medication with a contraindicated interaction to doxycycline (e.g., iron, barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin)
  • Current or planned use of doxycycline for a prolonged period (> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis
  • Prolonged antibiotic use (> 2 weeks) within the last 30 days prior to enrollment
  • Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, unless approved by the Protocol Team in writing
  • Positive NAAT for CT or NG or with evidence of untreated syphilis infection
  • Documented history of tetracycline allergy or self-reports an allergy to tetracyclines
  • Any other medical condition, medical/behavioral intervention, or other conditions that, in the opinion of the clinical site Principal Investigator/Investigator of Record (PI/IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results
  • All adolescent and adult young women who meet any of the following criteria will be excluded from this study:
  • Is male
  • Pregnant, or breastfeeding

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 13 and 34 years old?

Where is this trial?

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is for people who may get sexually transmitted infections (STIs). Approximately 580 African adolescent and young adult women ages 13-34 in Africa will be included in this study. Study participation is approximately 52 weeks (1 year). Participants will be randomized in a 1:1 ratio to receive doxycycline prophylaxis or standard of care.

The 2 groups in the trial

  • Doxycycline hyclate 200 mgTreatment being tested

    Participants randomized to the intervention arm will receive doxycycline hyclate 200 mg (2 x 100mg) administered orally once weekly, for the duration of 51 weeks.

    Treatment: Doxycycline hyclate

  • Standard of CareExisting treatment, for comparison

    Participants randomized to the standard-of-care arm alone will not receive doxycycline prophylaxis and will receive local standard of care for STI prevention per local guidelines.

    Treatment: Standard of Care for STI prevention

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Weekly Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Young African Women
Criteria questions
Built from NCT07884240, who can take part
Record updated
20 October 2026